These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32631933)

  • 21. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
    Hüsing A; Kaaks R
    Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Guzman A; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    Chest; 2022 Jan; 161(1):248-256. PubMed ID: 34252436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester.
    Crosbie PA; Balata H; Evison M; Atack M; Bayliss-Brideaux V; Colligan D; Duerden R; Eaglesfield J; Edwards T; Elton P; Foster J; Greaves M; Hayler G; Higgins C; Howells J; Irion K; Karunaratne D; Kelly J; King Z; Manson S; Mellor S; Miller D; Myerscough A; Newton T; O'Leary M; Pearson R; Pickford J; Sawyer R; Screaton NJ; Sharman A; Simmons M; Smith E; Taylor B; Taylor S; Walsham A; Watts A; Whittaker J; Yarnell L; Threlfall A; Barber PV; Tonge J; Booton R
    Thorax; 2019 Apr; 74(4):405-409. PubMed ID: 29440588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    Fu M; Travier N; Martín-Sánchez JC; Martínez-Sánchez JM; Vidal C; Garcia M;
    PLoS One; 2018; 13(4):e0195441. PubMed ID: 29621354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation.
    Field JK; Vulkan D; Davies MPA; Duffy SW; Gabe R
    Thorax; 2021 Feb; 76(2):161-168. PubMed ID: 33082166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the accuracy of the PLCO
    Jantzen R; Ezer N; Camilleri-Broët S; Tammemägi MC; Broët P
    CMAJ Open; 2023; 11(2):E314-E322. PubMed ID: 37041013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
    Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis.
    Feng X; Goodley P; Alcala K; Guida F; Kaaks R; Vermeulen R; Downward GS; Bonet C; Colorado-Yohar SM; Albanes D; Weinstein SJ; Goldberg M; Zins M; Relton C; Langhammer A; Skogholt AH; Johansson M; Robbins HA
    Lancet Digit Health; 2024 Sep; 6(9):e614-e624. PubMed ID: 39179310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
    PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.
    Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG
    BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving selection criteria for lung cancer screening. The potential role of emphysema.
    Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
    Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk.
    Crosbie PA; Gabe R; Simmonds I; Kennedy M; Rogerson S; Ahmed N; Baldwin DR; Booton R; Cochrane A; Darby M; Franks K; Hinde S; Janes SM; Macleod U; Messenger M; Moller H; Murray RL; Neal RD; Quaife SL; Sculpher M; Tharmanathan P; Torgerson D; Callister ME
    BMJ Open; 2020 Sep; 10(9):e037075. PubMed ID: 32912947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invitation strategies and participation in a community-based lung cancer screening programme located in areas of high socioeconomic deprivation.
    Goodley P; Balata H; Alonso A; Brockelsby C; Conroy M; Cooper-Moss N; Craig C; Evison M; Hewitt K; Higgins C; Johnson W; Lyons J; Merchant Z; Rowlands A; Sharman A; Sinnott N; Sperrin M; Booton R; Crosbie PAJ
    Thorax; 2023 Dec; 79(1):58-67. PubMed ID: 37586744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting lung cancer screenees using risk prediction models-where do we go from here.
    Tammemägi MC
    Transl Lung Cancer Res; 2018 Jun; 7(3):243-253. PubMed ID: 30050763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of the cancer risk management model lung cancer screening module.
    Flanagan WM; Evans WK; Fitzgerald NR; Goffin JR; Miller AB; Wolfson MC
    Health Rep; 2015 May; 26(5):11-8. PubMed ID: 25993046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Explaining differences in the frequency of lung cancer detection between the National Lung Screening Trial and community-based screening in Manchester, UK.
    Robbins HA; Zahed H; Lebrett MB; Balata H; Johansson M; Sharman A; Evans DG; Crosbie EJ; Booton R; Landy R; Crosbie PAJ
    Lung Cancer; 2022 Sep; 171():61-64. PubMed ID: 35917648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.